title: Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.
abstract: Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% ofStaphylococcus aureusisolates were inhibited by ≤2 μg/ml of omadacycline (MIC50/90, 0.12/0.25 μg/ml), including 100.0% of methicillin-susceptibleS. aureusisolates and 99.8% of methicillin-resistantS. aureusisolates. Omadacycline potencies were comparable forStreptococcus pneumoniae(MIC50/90, 0.06/0.06 μg/ml), viridans group streptococci (MIC50/90, 0.06/0.12 μg/ml), and beta-hemolytic streptococci (MIC50/90, 0.06/0.12 μg/ml) regardless of species and susceptibility to penicillin. Omadacycline was active againstEnterobacteriaceaeand was most active againstEscherichia coli(MIC50/90, 0.5/2 μg/ml),Enterobacter aerogenes(MIC50/90, 2/4 μg/ml),Klebsiella oxytoca(MIC50/90, 1/4 μg/ml), andCitrobacterspp. (MIC50/90, 1/4 μg/ml). Omadacycline was active againstHaemophilus influenzae(MIC50/90, 1/1 μg/ml) regardless of β-lactamase status and againstMoraxella catarrhalis(MIC50/90, 0.12/0.25 μg/ml). The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.|University of Iowa, Iowa City, Iowa, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Pfaller
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Huband
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Rhomberg
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA robert-flamm@jmilabs.com.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe; D005202:Asia, Eastern; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006801:Humans; D007843:Latin America; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D009656:North America; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D013754:Tetracyclines / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D013754:Tetracyclines; C000591640:omadacycline
keywords: aminomethylcycline; omadacycline; resistance; surveillance